Registro de fonte primária

RelevanteApresentação em congresso

Cullinan Therapeutics Reports Positive Velinotamig Phase 1b/2a Data in Refractory SLE at ACR 2026

Cullinan presented initial Phase 1b/2a results for velinotamig (BCMAxCD3 T cell engager) in refractory SLE showing clinical improvement in 8/9 patients, complete renal responses in 4/7 with baseline proteinuria, deep autoantibody and B-cell reductions, and a favorable safety profile with no DLTs, ICANS or Grade >=3 CRS. This is the first clinical data announcement for the asset in SLE.

Fatos principais

Arquivado
8 de nov. de 2026, 12:00
Evento
Apresentação em congresso
Direção
Positivo
Fonte
SEC 8-K
Confiança
Com fonte
Calendário
Apresentação em congresso · 8 de nov. de 2026 · Resultado não registrado
Resposta SLEDAI-2K
8 de 9 doentes avaliáveis com redução de >=4 pontos
Redução da proteinúria
5 de 7 doentes avaliáveis
Resposta renal completa
4 de 7 doentes avaliáveis com proteinúria basal >500 mg/24h

Trecho da fonte

EX-99.1 2 cgem-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Velinotamig, a BCMAxCD3 T Cell Engager, Achieves Complete Renal Responses and Significantly Reduces Disease Activity in Systemic Lupus Erythematosus in Data Presented at ACR Convergence 2026 Clinically meaningful improvement in disease activity among 8 of 9 evaluable patients, including rapid and marked reductions in proteinuria with complete renal responses Deep and sustained reduction in pathogenic autoantibodies and IgG reduction underscore potential in plasma-cell driven diseases Favorable safety profile in patients with refractory SLE CAMBRIDGE, Mass., Nov. 8, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-mo

SEC 8-K

Cullinan Therapeutics Reports Positive Velinotamig Phase 1b/2a Data in Refractory SLE at ACR 2026 | SimianX AI